SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.51-1.3%Jan 16 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BulbaMan who wrote (5098)12/11/2001 9:19:39 AM
From: Biomaven  Read Replies (2) of 52153
 
Thanks, BulbaMan.

One thing worth adding is that in biotech there are smart shorts (like Avalon) and dumb shorts (like Anthony@ etc.). When you have the dumb shorts and their even dumber followers in a stock things tend to get unpleasant. But I think worst of all are the sleazier hedge funds who are smart enough to make a convincing (but specious) argument.

Short positions in many biotechs have been climbing. For example, look at SCIO, an Avalon short. Both the price and the short position have been showing a steady increase since the September low, with the November short position a massive 7.7m shares.

One nice place to look at short positions over time is:

viwes.com

I noticed MOGN has had a dramatic increase in short position in November, doubling from October.

Remember always that raw short numbers can be very misleading because often large short positions are hedges against convertible or option/warrant holdings.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News